Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mihail Obrocea, MD
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
39 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 75334
Toorak Gardens, Australia
- Site Reference Id/investigator# 75335
Woodville South, Australia
- Site Reference Id/investigator# 75337
Antwerp, Belgium
- Site Reference Id/investigator# 75336
Brussels, Belgium
- Site Reference Id/investigator# 75338
Leuven, Belgium
- Site Reference Id/investigator# 75333
Milan, Italy
- Site Reference Id/investigator# 75415
Milan, Italy
- Site Reference Id/investigator# 75344
Bialystok, Poland
- Site Reference Id/investigator# 75339
Krakow, Poland
- Site Reference Id/investigator# 75341
Lublin, Poland
- Site Reference Id/investigator# 75342
Poznan, Poland
- Site Reference Id/investigator# 75343
Poznan, Poland
- Site Reference Id/investigator# 75345
Szczecin, Poland
- Site Reference Id/investigator# 75340
Wroclaw, Poland
- Site Reference Id/investigator# 75346
Moscow, Russia
- Site Reference Id/investigator# 75348
Moscow, Russia
- Site Reference Id/investigator# 75347
Saint Petersburg, Russia
- Site Reference Id/investigator# 75349
Barcelona, Spain
- Site Reference Id/investigator# 75351
Barcelona, Spain
- Site Reference Id/investigator# 75352
Barcelona, Spain
- Site Reference Id/investigator# 75350
Girona, Spain
- Site Reference Id/investigator# 75353
Madrid, Spain
- Site Reference Id/investigator# 75354
Stockholm, Sweden
- Site Reference Id/investigator# 75355
Umeå, Sweden
- Site Reference Id/investigator# 75416
Bellinzona, Switzerland
- Site Reference Id/investigator# 75281
Anaheim, California, United States
- Site Reference Id/investigator# 75275
Redondo Beach, California, United States
- Site Reference Id/investigator# 75296
Sunrise, Florida, United States
- Site Reference Id/investigator# 75299
Atlanta, Georgia, United States
- Site Reference Id/investigator# 75300
Savannah, Georgia, United States
- Site Reference Id/investigator# 75301
Hinsdale, Illinois, United States
- Site Reference Id/investigator# 75274
Baltimore, Maryland, United States
- Site Reference Id/investigator# 75294
Jackson, Missouri, United States
- Site Reference Id/investigator# 75279
Oklahoma City, Oklahoma, United States
- Site Reference Id/investigator# 75295
Corpus Christi, Texas, United States
- Site Reference Id/investigator# 75280
Dallas, Texas, United States
- Site Reference Id/investigator# 75297
Danville, Virginia, United States
- Site Reference Id/investigator# 75298
Williamsburg, Virginia, United States
- Site Reference Id/investigator# 75278
Green Bay, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2007
- Primary completion
- 31 Oct 2008
- Completion
- 31 Oct 2009
- Last update posted
- 18 Jan 2013
- Registered enrollment
- 138
- Registry id
- NCT00635193
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.